Testing of chemicals

Lists of projects on the AOP development programme workplan

 

 

 

SECTION 1: Development of an adverse outcome pathway

Project 1.1: The Adverse Outcome Pathways for Skin Sensitisation Initiated by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

 

Project 1.2: The Adverse Outcome Pathways for Nonpolar Narcosis

Lead:

Inclusion in work plan:

United States

2012

 

Project 1.3: The Adverse Outcome Pathways for Acetylcholinesterase Inhibition

Lead:

Inclusion in work plan:

United States

2012

 

Project 1.4: Adverse Outcome Pathways for Five Cell Signalling Pathways Associated with Cell Proliferation and Differentiation that are Conserved Across Species

Lead:

Inclusion in work plan:

Secretariat + consultant

2010

 

Project 1.5: Two Adverse Outcome Pathways for Mitochondrial Toxicity

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

 

Project 1.6: The Adverse Outcome Pathways for Embryonic Vascular Disruption and Developmental Defects

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.7: The Adverse Outcome Pathways for Sustained Activation of the Avian Aryl Hydrocarbon Receptor

Lead:

Inclusion in work plan:

Canada, BIAC

2013

AOP1: AHR1 activation leading to developmental abnormalities and embryolethality (in birds)

AOP2: Sustained AhR Activation leading to Rodent Liver Tumour promotion 

Project 1.8: See Project 2.8

 

 

Project 1.9: The Adverse Outcome Pathway on Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready October 2013.

Project 1.10: The Adverse Outcome Pathway on Xenobiotic Induced Inhibition of Thyroperoxidase and Depressed Thyroid Hormone Synthesis and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.11: The Adverse Outcome Pathways for Heritable Germ Cell-Derived Disease (3 AOPs)

Lead:

Inclusion in work plan:

Canada

2013

AOP 1: Alkylation of DNA in male pre-meiotic germ cells causing inherited mutation

AOP 2: Chemical interaction with tubulin in oocytes leading to inherited aneuploidy

AOP 3: Stable bulky DNA adducts in male pre-meiotic germ cells causing point mutation leading to inherited DNA sequence mutation

Project 1.12: The Adverse Outcome Pathways linking Aromatase Inhibition, Androgen Receptor Agonism, Estrogen Receptor Antagonism, or Steroidogenesis Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species

Lead:

Inclusion in work plan:

United States

2013

AOP1: Androgen receptor agonism leading to reproductive dysfunction

AOP2: Aromatase inhibition leading to reproductive dysfunction (in fish)

AOP3: Estrogen receptor antagonism leading to reproductive dysfunction

AOP4: Estrogen receptor agonism leading to reproductive dysfunction

AOP5: Androgen receptor antagonism leading to reproductive dysfunction

Project 1.13: The Adverse Outcome Pathway on Neurotoxicant-induced Neuroinflammation: A Converging Key Event in an Adverse Outcome Pathway

Lead:

Inclusion in work plan:

Switzerland

2013

AOP1: Binding to electron chain transfer complexes in the mitochondria can trigger neuroinflammation and lead to neurodegeneration

AOP2: Binding to SH/selen-proteins can trigger neuroinflammation leading to neurodegeneration

AOP3: Binding to glutamatergic ionotropic receptors can trigger neuroinflammation leading to neurodegeneration

AOP4: Binding of antagonists to NMDAR can trigger neuroinflammation leading to neurodegeneration 

Project 1.14: The Adverse Outcome Pathways from Protein Alkylation to Liver Fibrosis

Lead:

Inclusion in work plan:

 

European Commission

2013

 

Project 1.15: The Adverse Outcome Pathways for Neurotoxicity Induced by GABAA Receptor Inhibition

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.16: The Adverse Outcome Pathway Describing Hematotoxicity due to Nitroaromatics and N-hydroxyl anilines

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.17: The Adverse Outcome Pathway on CAR and PPARα-mediated Pathways to Non-genotoxic Rodent Liver Cancer

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.18: The Adverse Outcome Pathway on CAR and PXR-mediated Pathways to Rodent Liver Hyperplasia

Lead:

Inclusion in work plan:

United States

2013

 

Project 1.19: The Adverse Outcome Pathway from Bile Salt Export Pump Inhibition to Cholestatic Liver Injury

Lead:

Inclusion in work plan:

Belgium

2013

 

Project 1.20: The Adverse Outcome Pathway for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

ICAPO

2013

 

Project 1.21: Three Adverse Outcome Pathways from Peroxisome Proliferator-activated Receptors (PPARs) Activation Leading to Reproductive Toxicity in Rodents

Lead:

Inclusion in work plan:

European Commission

2014

AOP1: PPAR alpha activation leading to decreased fertility upon utero exposure in rodent males

AOP2: PPARγ activation leading to decreased fertility in adult female rodents

AOP3: PPARα activation leading to decreased fertility in male rodents 

Project 1.22: The Adverse Outcome Pathway from Binding of Antagonists to NMDAR during Brain Development (Synaptogenesis) Induces Impairment of Learning and Memory Abilities

Lead:

Inclusion in work plan:

European Commission

2014

 

Project 1.23: The Adverse Outcome Pathway from Binding of Agonists to NMDAR in Adult Brain Causes Excitotoxicity that Mediates Neuronal Cell Death, Contributing to Reduction of Cognitive Functions

Lead:

Inclusion in work plan:

European Commission

2014

 

Project 1.24: The Adverse Outcome Pathway from Cyp2E1 Stabilization by Substrate Binding Leading to Liver Cancer

Lead:

Inclusion in work plan:

Canada

2014

Project 1.25: The Adverse Outcome Pathway from Induction of Secretion of Inflammatory Cytokines Leading to Lung Emphysema

Lead:

Inclusion in work plan:

Canada

2014

 

Project 1.26: Androgen receptor-mediated pathway to liver cancer

Lead:

Inclusion in work plan:

United States

2014

 

Project 1.27: AhR activation leading to embryo toxicity in fish

Lead:

Inclusion in work plan:

United States and Canada

2014

 

Project 1.28: The Adverse Outcome Pathway for Inhibition of Na+/I- symporter (NIS) decreases TH synthesis leading to learning and memory deficit in children

Lead:

Inclusion in work plan:

European Commission

2014

Project 1.29: A catalog of putative AOPs that will enhance the utility of US EPA Toxcast high throughput screening data for hazard identification

Lead:

Inclusion in work plan:

United States

2014

 

Exposure to Mixtures of Metals and Neurodevelopmental Outcomes

Lead:

Inclusion in work plan:

United States

Under revision

 

 

 

 

SECTION 2: Development of an adverse outcome pathway case study

Project 2.1: The Adverse Outcome Pathways- Case Studies Using Aquatic Organism

Lead:

Inclusion in work plan:

United Kingdom and Japan

2013

 

Project 2.2: The Adverse Outcome Pathway on Hepatotoxicity due to 2,4,6-trinitrotoluene

Lead:

Inclusion in work plan:

United States

2013

 

Project 2.3: The Adverse Outcome Pathway on Energy Metabolism by 2,6-Dinitroluene

Lead:

Inclusion in work plan:

United States

2013

 

Project 2.4: The Adverse Outcome Pathway for Adipogenic Phenotype Mediated via Activation of PPARy

Lead:

Inclusion in work plan:

United States

2014

 

Project 2.5: Percellome Toxicogenomics Approach for AOP Binding: Case Study on Pentachlorophenol

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.6: Immunosuppression Initiated by Metal

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.7: A Non-mutagenic AOP for Nasal Tumours from Exposure to Weakly Genotoxic, Endogenous and Low Molecular Weight Substances: Vinyl Acetate, Acetaldehyde and Propylene Oxide

Lead:

Inclusion in work plan:

BIAC

2014

 

Project 2.8: The Adverse Outcome Pathways for Mutagenic Modes of Action for Cancer

Lead:

Inclusion in work plan:

United StatesBIAC

2014

 

Project 2.9: The Adverse Outcome Pathway for Arthropathy/Tendinopathy Induced by Fluoroquinolones

Lead:

Inclusion in work plan:

United States

2014

 

 

SECTION 3: Guidance documents related to adverse outcome pathway development including its evaluation

Project 3.1: Development of a Template for Recording Adverse Outcome Pathways (AOPs) and Associated Guidance Relating to How to Assess its Completeness

Lead:

Inclusion in work plan:

 

Secretariat

2011

 

Completed: Guidance and template published (No. 184 in OECD Series on Testing and Assessment)

 

SECTION 4:  Knowledge management tool

Project 4.1: Web Based AOP Knowledge Management Tool

Lead:

Inclusion in work plan:

United States

2013

 

Project 4.2: Adverse Outcome Pathways Knowledge Base (AOP-KB)

Lead:

Inclusion in work plan:

European Commission, United States

2013

 

Project 4.3: Effectopedia

Lead:

Inclusion in work plan:

EC, US and Secretariat

2013

 

 

SECTION 5: Others

Project 5.1: In vitro test method development strategy for the OECD Skin Sensitisation AOP

Lead:

Inclusion in work plan:

EC/ECVAM

2013

 

Project 5.2: Guidance document for describing non-guideline in vitro assays

Lead:

Inclusion in work plan:

VMG-NA

2013

 

 

Related Documents